2009-08-25

What is the Nation Level Response to PF11?

Central and South American countries are closing schools and rationing health care while Australia is evacuating some hospitals of all patients other than Influenza management due to rapid spread across floors and depth of morbidity. Vietnam closed all schools in the capital in mid-August. No nation’s public health leaders are reporting accurate case counts or death counts, but a careful and ongoing counting of reports correlated with the medical data demonstrates documentation for 522 deaths in the US, 450 in Argentina (since mid-May with 400 awaiting confirmation for a potential total of 850 deaths) and 413 in Brasil (>10% pregnant women). The death counts in South America are rising in some countries as much as 40% every 7 days even with the WHO blackout on measuring and reporting to the public. Though strong intervention measures are reportedly being invoked, many South American countries have more than 100 confirmed PF11 casualties. The UK death count increased by 30% this week. On the European coast, Spain estimates 10,000 new cases per week with at least three concurrent PF11 Variant strains.

Keep in mind that between 31% and 60% of the tests commonly used for PF11 have provided a false negative result. Slightly less than half of all cases that have tested negative may have been positive, suffering from Pandemic Influenza and spreading contagion. As you may realise from the CDC admission during the early phases of this pandemic on June 25th of 1 million cases in the United States when less than 40,000 had been chronicled, surveillance is far less than superficial. The American CDC allowed a factor of 25 times the number of confirmed cases to achieve the estimated total. That factor is a very important number.

Using the CDC-supplied ratio of confirmed to estimated actual cases, we may also measure confirmed to actual deaths. Multiply 522 CDC confirmed US deaths by 25 and you arrive at more than 13,000 deaths across the first 90 days, 13,000 deaths from a “mild” Influenza, deaths in age groups that are only highly represented in a High-CFR pandemic? Political issues are at play, obviously and the public will not at any juncture of this pandemic be provided accurate numbers. We will track the deltas, however, to measure the progressions using any data that is available. We are aware of many cases, some personally, that exhibited all signals of Influenza presentation, progression and expiration, but that have been officially recorded otherwise, blatantly in some cases. These political outcroppings of a failed public health policy were also predicted four years ago and are not a surprise to us or to others tracking this issue closely.

At the same time, we are watching the many different viral strains from around the globe continue to upgrade their genetics. Anti-viral (Neuraminidase Inhibitors) drug resistance in both widely available commercial categories is essentially guaranteed as you will see in our trailing analyses. The vaccine antigen being produced today will be late for the Fall and veers markedly in genetic resemblance from the viral specimens presently being sequenced from active circulation. The current Pandemic H1N1 continues to escape the vaccine target by accumulating and conserving changes each week.

The vaccine seed stock strain for this ostensibly “mild” Influenza is so powerful that growth cannot be well-controlled in the lab and little antigen is harvested. Measure the facts on a timeline. The vaccine is announced for mid-October delivery with a 5 week seroconversion period in the host. You can easily see that the earliest possible point of any benefit to anyone, if the vaccine is safe and matches, is very late November, another 90 days after school starts and well into winter. You’ve seen the impact of this virus in the first 90 days, in 3 months of warm weather in America. We haven’t yet seen this virus at work in the Northern Hemisphere with the Fall and Winter versions operating in colder weather.

Fringe ideas for “extending” the antigen have been introduced and are becoming entrenched in the discussions between vaccine purchasers and producers. Adjuvants that are scientifically known to be highly toxic, including MPL and squalene, are offering a politically-expedient solution to our leaders at the cost of public health.

Though most in the scientific community publicly announce that they rely on pure data, on facts, the current set of circumstances clearly demonstrates the scientific community’s reliance on blind faith in rapidly resisted anti-virals and easily evaded vaccines as primary mediation measures. At this time, the facts don’t support their conclusions, nor do the data support their actions. The medical and scientific community have super-imposed faith and hope in a time when we have trusted them to discover truth and use facts to protect us. Faith is an exceptional practice when placed properly; whereas, a misplaced faith will typically result in a negative impact.

No Hallelujah Pill and No Hallelujah Vaccine
will reliably save us from this virus.

The mediation measures being put in place by our leaders are but minor impact measures that will be used due to ease of execution and lack of Knowledge of the citizenry. Those measures also carry mid-term and long-term negative health effects for the human population, including allowing a higher death rate than other, more reliable, mediation measures. The failed surveillance coupled with a “managed message” campaign will have a higher negative impact on the population than any other aspect of our national response failure. We are being actively triaged while being managed with a disinformation flow stating that first rate health care is being provided and that our interests are foremost in the leaders’ minds.

Science, in a pure form, looks at data, examines the facts and makes transparent decisions based on those facts. Science, in a pure form, is not occurring widely in relation to this pandemic.

For additional background on the clinical and epidemiological observational facts concerning Pandemic Influenza H1N1, please refer to the Table of Contents for PF11 Trends & Issues, Mid-Term.


Please visit GeneWurx.com for insight into the latest published studies.

GeneWurx.com